174258-31-2

Upstream product

• 100-83-4 meta-hydroxybenzaldehyde 
• 103788-61-0 (5-methyl-2-phenyl-4-oxazolyl)methyl chloride 
• 159017-85-3 3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzaldehyde 

Downstream Products

• 174258-32-3 4-{[3-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole 
• 250601-74-2 ethyl (E)-6-{3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-6-phenylhexanoate 
• 250601-73-1 methyl (E)-4-{3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyrate 
• 250602-86-9 N-{3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxy}phtalimide 
• 250602-87-0 3-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyamine 

Relevant academic research and scientific papers

A back-to-front fragment-based drug design search strategy targeting the DFG-out pocket of protein tyrosine kinases

We present a straightforward process for the discovery of novel back pocket-binding fragment molecules against protein tyrosine kinases. The approach begins by screening against the nonphosphorylated target kinase with subsequent counterscreening of hits against the phosphorylated enzyme. Back pocket-binding fragments are inactive against the phosphorylated kinase. Fragment molecules are of insufficient size to span both regions of the ATP binding pocket; thus, the outcome is binary (back pocket-binding or hinge-binding). Next, fragments with the appropriate binding profile are assayed in combination with a known hinge-binding fragment and subsequently with a known back pocket-binding fragment. Confirmation of back pocket-binding by Yonetani-Theorell plot analysis progresses candidate fragments to crystallization trials. The method is exemplified by a fragment screening campaign against vascular endothelial growth factor receptor 2, and a novel back pocket-binding fragment is presented.

Studies on non-thiazolidinedione antidiabetic Agents. 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents

We previously reported that (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl) methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid (3) showed potent glucose and lipid lowering effects in genetically obese and diabetic mice, KKA y. This compound a

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.

ARALKYL-N-HYDROXYUREAS AS INHIBITORS OF 5-LIPOXYGENASE AND OXIDATION OF LOW DENSITY LIPOPROTEIN

This invention relates to compounds compounds useful in treating diseases mediated by one or more leukotrienes or oxidative modification of low density lipoprotein such as inflammation, bronchoconstriction or atherosclerosis. The compounds of this inventi